These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38925962)

  • 1. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
    Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
    Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
    Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
    Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy.
    Wang Q; Bu Q; Xu Z; Liang Y; Zhou J; Pan Y; Zhou H; Lu L
    Clin Mol Hepatol; 2024 Jul; 30(3):515-538. PubMed ID: 38726504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patchouli alcohol alleviates metabolic dysfunction-associated steatohepatitis via inhibiting mitochondria-associated endoplasmic reticulum membrane disruption-induced hepatic steatosis and inflammation in rats.
    Xie X; Liao Y; Lin Z; Luo H; Wei G; Huang N; Li Y; Chen J; Su Z; Yu X; Chen L; Liu Y
    Int Immunopharmacol; 2024 Sep; 138():112634. PubMed ID: 38971107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of the analgesic Neurotropin for MASLD/MASH treatment.
    Tsuchiya T; Kim SY; Matsuda M; Kim J; Stotland A; Naiki M; Seki E
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39023282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice.
    Fondevila MF; Novoa E; Fernandez U; Dorta V; Parracho T; Kreimeyer H; Garcia-Vence M; Chantada-Vazquez MP; Bravo SB; Porteiro B; Cabaleiro A; Koning M; Senra A; Souto Y; Verheij J; Guallar D; Fidalgo M; Meijnikman AS; da Silva Lima N; Dieguez C; Gonzalez-Rellan MJ; Nogueiras R
    Mol Metab; 2024 Jul; 85():101962. PubMed ID: 38815625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
    Saito T; Tsuchishima M; Tsutsumi M; George J
    J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma.
    Wang YL; Liu C; Yang YY; Zhang L; Guo X; Niu C; Zhang NP; Ding J; Wu J
    FASEB J; 2024 Jul; 38(13):e23766. PubMed ID: 38967214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.
    Jeong BK; Choi WI; Choi W; Moon J; Lee WH; Choi C; Choi IY; Lee SH; Kim JK; Ju YS; Kim P; Moon YA; Park JY; Kim H
    Nat Commun; 2024 Aug; 15(1):6506. PubMed ID: 39090079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.